Save Product
Product Details
Synonym
EGFRvIII
Source
FITC-Labeled Human EGFRvIII Protein, His Tag (EGI-HF2H7) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Ser 378 (Accession # NP_001333870.1). It is the FITC labeled form of Human EGFRvIII, His Tag (Cat. No. EGI-H52H4).
Predicted N-terminus: Leu 25
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 40.5 kDa. The protein migrates as 55-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Conjugate
FITC
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 535 nm
Labeling
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.
Protein Ratio
The FITC to protein molar ratio is 2-4.
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
FITC-Labeled Human EGFRvIII Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Customer Reviews Writing Reviews
Background
The type III EGF deletion mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors. This tumor-specific antigen is ligand-independent, contains a constitutively active tyrosine kinase domain, and has been shown to be present in a number of human malignancies. EGFRvIII has been selected as a target for CAR-modified T-cell studies in recent years.
Recent Advances
Drug Development Progress- English Name：
Epidermal growth factor receptor variant III
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
13 Details
- Highest Development Stage：
Phase 2 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing